This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Life Sciences Research Partners Vzw. Active years: 2010-2011.
Company Filing History:
1 out of 97 
1 out of 41 
Years Active: 2010-2011
Title: The Innovations of Jean Guy Gilles
Introduction
Jean Guy Gilles is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 2 patents, his work has the potential to impact the treatment of various medical conditions.
Latest Patents
Gilles' latest patents include groundbreaking inventions in the realm of monoclonal antibodies. One of his patents focuses on an anti-idiotypic antibody that neutralizes the inhibitor activity of a factor VIII inhibitor antibody. This invention is particularly relevant for the treatment of hemophilia A, as it involves a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII. Another patent relates to new antibodies that bind to the A2 domain of Factor VIII and inhibit its coagulation activity. These antibodies are designed for therapeutic strategies aimed at eradicating Factor VIII inhibitors and can be used in pharmaceutical compositions for treating cardiovascular disorders.
Career Highlights
Throughout his career, Jean Guy Gilles has worked with various organizations, including Life Sciences Research Partners and Laboratoire Français Du Fractionnement Et Des Biotechnologies. His expertise in biotechnology and antibody development has positioned him as a key figure in his field.
Collaborations
Gilles has collaborated with notable professionals such as Marc G Jacquemin and Jean-Marie Saint-Remy. These collaborations have further enhanced his research and development efforts in the biotechnology sector.
Conclusion
Jean Guy Gilles is a distinguished inventor whose work in antibody development has the potential to revolutionize treatments for hemophilia A and cardiovascular disorders. His contributions to biotechnology are significant and continue to influence the field.